Compass Therapeutics Inc Stock Price, News & Analysis

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, has announced the pricing of an upsized public offering totaling $120 million. The offering consists of 33,290,000 shares of common stock priced at $3.00 per share and pre-funded warrants to purchase 6,710,000 shares at $2.9999 per warrant.

The underwriters have a 30-day option to purchase up to 6 million additional shares. The offering is expected to close around August 14, 2025. The company plans to use the proceeds for commercial readiness preparations, research and clinical development of product candidates, and general corporate purposes.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase additional shares under the same terms.

The company plans to use the proceeds for commercial readiness preparations, research and clinical development of its product candidates, and general corporate purposes. Jefferies, Piper Sandler, and Guggenheim Securities are serving as joint active bookrunning managers for the offering.

The offering will be conducted through a shelf registration statement on Form S-3 that was declared effective by the SEC on September 6, 2024.

Compass Therapeutics (NASDAQ:CMPX) reported Q2 2025 financial results and provided updates on its oncology pipeline. The company reported a net loss of $19.9 million ($0.14 per share), compared to $13.1 million in Q2 2024. Key highlights include promising survival data for tovecimig in biliary tract cancer, with secondary endpoint analysis now expected in Q1 2026.

In the CTX-8371 Phase 1 trial, two significant partial responses were observed in post-checkpoint inhibitor settings, including 100% tumor reduction in a lung cancer patient and >90% reduction in a breast cancer patient. The company's new drug CTX-10726 showed superior results compared to ivonescimab in preclinical studies.

Compass ended Q2 with $101 million in cash, providing runway into 2027. R&D expenses increased 47% year-over-year to $16.4 million, primarily due to manufacturing costs for tovecimig and CTX-10726.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, will host its Q2 2025 financial results conference call on August 11, 2025, at 8:00 AM ET. The presentation will include updates on multiple programs including the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726.

Investors can access the webcast via the provided link or join by phone using the dial-in numbers. A replay will be available for 90 days on Compass' Events page.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company will engage in a fireside chat scheduled for June 5, 2025, from 11:05 to 11:35 AM ET. The presentation will be accessible via webcast and will remain available for replay on Compass' Events page for 90 days following the event.

Compass Therapeutics (NASDAQ: CMPX) reported significant progress in Q1 2025, highlighted by tovecimig meeting its primary endpoint in the Phase 2/3 COMPANION-002 study for biliary tract cancer (BTC). The drug achieved a 17.1% overall response rate compared to 5.3% for paclitaxel alone. The company also advanced other pipeline candidates, including CTX-10726 (PD-1 x VEGF-A bispecific antibody) and CTX-8371.

Financial results showed a net loss of $16.6 million ($0.12 per share) compared to $10.8 million in Q1 2024. R&D expenses increased 37% to $13.1 million, while G&A expenses rose 51% to $4.9 million. The company maintains a strong financial position with $113 million in cash, providing runway into 2027.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in two major investor events in May 2025. The company will present at The Citizens Life Sciences Conference in New York on May 8, 2025, at 1:30 PM ET, and at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025, at 11:30 AM ET. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.

Compass Therapeutics (NASDAQ: CMPX) presented promising preclinical data at the AACR Annual Meeting regarding the combination of CTX-471 and tovecimig in cancer treatment. The research demonstrated enhanced anti-tumor efficacy in checkpoint-refractory models.

The study showed that CTX-471 monotherapy was effective in multiple murine models resistant to immune checkpoint inhibitors. When combined with tovecimig, the treatment showed increased effectiveness through enhanced innate and adaptive anti-tumor immunity, improved tumor cell killing, and increased antigen presentation and interferon signaling.

The research utilized novel mouse tumor models engineered to mimic HLA loss in patients, including CT26B2m and MC38B2m knockout models. The combination therapy showed particular promise in cases where conventional checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, have failed.

Compass Therapeutics (CMPX) has initiated dosing in a new Investigator Sponsored Trial (IST) evaluating tovecimig as a first-line treatment for biliary tract cancer (BTC). The trial, conducted at MD Anderson Cancer Center, will study tovecimig in combination with gemcitabine, cisplatin, and durvalumab in approximately 50 patients with unresectable or metastatic BTC.

The study includes a safety run-in phase with 12 patients, followed by an expansion phase with 38 additional patients. Primary objectives include assessing 6-month progression-free survival, safety, and determining maximum tolerated dose. The company recently announced that tovecimig met its primary endpoint in their ongoing Phase 2/3 second-line BTC study, with secondary endpoint results expected in Q4 2025.